Document Detail

Stroke in chronic kidney disease: prevention and management.
MedLine Citation:
PMID:  18178791     Owner:  NLM     Status:  MEDLINE    
The incidence of stroke is elevated among individuals with kidney disease. Traditional risk factors seem to account for much but not all of this excess risk. Blood pressure control is the most important aspect of stroke prevention. Multiple classes of antihypertensive agents, including diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers, have reduced stroke risk. Some physiologic and clinical evidence suggests that angiotensin II receptor blockers may offer superior benefit to that of angiotensin-converting enzyme inhibitors for the same level of blood pressure control; however, few head-to-head trials have compared these two agent classes directly using stroke as an outcome.
Raymond R Townsend
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical journal of the American Society of Nephrology : CJASN     Volume:  3 Suppl 1     ISSN:  1555-905X     ISO Abbreviation:  Clin J Am Soc Nephrol     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-07     Completed Date:  2008-03-05     Revised Date:  2013-06-06    
Medline Journal Info:
Nlm Unique ID:  101271570     Medline TA:  Clin J Am Soc Nephrol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S11-6     Citation Subset:  IM    
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use
Brain Ischemia / complications
Chronic Disease
Hypertension / complications,  drug therapy
Kidney Diseases / complications*
Risk Assessment
Stroke / etiology,  prevention & control*,  therapy*
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Contrast-induced nephropathy: what are the true clinical consequences?
Next Document:  Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers...